Atrial fibrillation and subcutaneous monitoring : Will it change our daily practice ? Aymeric MENET Lille January 2016.

Slides:

Advertisements

Similar presentations

Automatic QRS Complex Detection Algorithm Designed for a Novel Electrocardiogram Recording Device Co-authors Kenneth Egstrup, OUH Svendborg Hospital Jens.

Advertisements

Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370: Presented by Kris Huston | July 21, 2014.

Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.

Ian Graham et al. European Heart Journal 2007;28:

Jeff Healey MD, MSc, FHRS McMaster University

Cardioversion of Atrial Fibrillation Clinical Issues Christopher Granger, MD Director, Cardiac Care Unit Duke University Medical Center December 2007.

Arrhytmia In Heart Failure

APIXABAN NELLA SPAF 21 maggio 2015 ROMA Dott. Sergio Agosti Cardiologo, Ospedale Novi Ligure (AL)

New Agents Heather Kertland, PharmD.

ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.

How Much AF is Too Much AF? Do I Initiate Anticoagulation Based on AF Detected on Device Monitoring? Kenneth W. Mahaffey, MD, FACC Professor of Medicine,

XPECT Study Physician Presentation. XPECT Study 1 Purpose Quantify the performance of the first implantable leadless cardiac monitor (ICM) with dedicated.

VBWG In-hospital course of stroke patients with vs without AF Steger C et al. Eur Heart J. 2004;6:in press. More severe stroke on admission Lower Barthel.

SWEDMAF Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Carina Blomstrom-Lundqvist SWEDMAF Trial.

Presented by Renato D. Lopes, MD, PhD, Duke Clinical Research Institute, Duke University, USA for the ARISTOTLE investigators. Efficacy and Safety of Apixaban.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.

Gianluca Botto, FESC Presidente AIAC Associazione Italiana Aritmologia e Cardiostimolazione FA Sintomatica e Asintomatica Epidemiologia e Rischio Clinico.

Stoke On Trent CCG – Atrial Fibrillation Service AF Nurse in GP Practice Interfacing Primary and Secondary Care for AF Stroke Prevention Jodie Williams.

Cost effectiveness of AF monitoring strategies in a post-stroke population LAUREN E. CIPRIANO JEFF HEALEY OMAR AKHTAR KAREN LEE LUCIANO A. SPOSATO APRIL.

Γεώργιος Ντάιος Παθολογική Κλινική, Πανεπιστήμιο Θεσσαλίας Διαχείριση αντιπηκτικής αγωγής εν όψει προγραμματισμένων επεμβατικών πράξεων.

R2. 최태웅 / Pf. 김진배. BACKGROUND  Ischemic stroke : leading causes of death and disability : cause remains unexplained after routine evaluation → Cryptogenic.

1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.

Cryptogenic Stroke and AF

Postulated Association Between AF and Stroke

Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated with Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.

CRT 2017: Putting LAA closure in the age of DOACs into perspective

Heart Valve Thrombosis & Neuro-Outcomes

How Do We Incorporate Patient Perspectives Into Clinical Trial Design?

An approach to using risk scores for stroke and bleeding in clinical practice. An approach to using risk scores for stroke and bleeding in clinical practice.

David R. Holmes, Jr., M.D. Mayo Clinic, Rochester

Figure 1 Flow chart diagram of high-risk group AF patients

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

Department of Cardiology Bern University Hospital

Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation (ISAR-TRIPLE Trial) - press conference - Katrin.

No evidence that AF type significantly impacts stroke risk

Epidemiology of Atrial Fibrillation in Europe:

Silent No More:.

Monitoring Continuum ISSUE-3 Atrial Fibrillation Classification.

Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

Oral Anticoagulants in AFa,b A Brief History.

Selecting NOACs for High-Risk Patients

Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

MAGIC-AF Trial design: Patients with persistent atrial fibrillation (AF) and remaining in AF after pulmonary vein isolation alone were randomized to either.

Efficacy and Safety of Edoxaban in Patients With AF and HF

Nat. Rev. Cardiol. doi: /nrcardio

Atrial Fibrillation.

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

Identifying High-Risk AF Patients

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

ALBATROSS Trial design: Patients with MI without heart failure were randomized to an IV bolus of potassium canrenoate 200 mg as early as possible, then.

Study Background and Rationale Updated October 24, 2018

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Nazem Akoum, MD, MS, FACC, FHRS Associate Professor of Medicine

Statistical Challenges Related to Population Screening for AF Christine M. Albert, MD, MPH Director, Center for Arrhythmia Prevention, Brigham.

CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.

What is “AF Burden”?. What is “AF Burden”? AF Burden and Stroke Risk ASSERT Study.

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter

Nat. Rev. Cardiol. doi: /nrcardio

(p for noninferiority = 0.01)

Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.

Forest plot illustrating the risk ratio of any bleeding and GRADE assessment. AF, atrial fibrillation; DOAC, advent of direct oral anticoagulants; PCI,

Figure 8. Stroke prevention strategy in patients with AF

Gianluigi Savarese et al. JCHF 2016;4:

Forest plot illustrating the risk ratio of major bleeding

Presenter Disclosure Information

The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.

Presentation transcript:

Atrial fibrillation and subcutaneous monitoring : Will it change our daily practice ? Aymeric MENET Lille January 2016

No Disclosure

What we knew before the subcutaneous monitoring ,3-0,71à Thromboembolism risk/year in AF without treatment = CHADS2VA2SC Aspirin = ↓ 22% Oral Anticoagulants = ↓ 66% Risk of thromboembolism x 3-5 Risk of death x 2, HF, Dyspnea, QoL

Risk of stroke according to the FA type Friberg, Eur Heart Journal 2010 Paroxystic vs permanent Hart, JACC 2000 Intermittent vs permanent

Risk of stroke according to the FA type Vanassche, Eur Heart Journal 2015 Paroxystic vs permanent But Asymtomatic AF is very frequent Bad detection with Holters (AF > 5min) -44 % si Holter 24h, -50% si Holter 1 semaine -65% si holter de 1 mois Botto GL, J Cadiov Imaging 2009

What we learned from the subcutaneous monitoring Burden of AF and stroke Temporal link between AF and stroke

1) AF burden and ThromboEmbolic risk YearStudy Stroke / year rate (n) N (n en AF)Cut-off 2003MOST0,6 vs 2 (10)312 (160)5 min 2005Cappuci et al1,9 (14)743 (743)24h 2009TRENDS1,1 vs 2,4 (40)2486 (1389)>5.5h 2009Botto2,5 (14)568 (568) 5 minutes – >24h 2012 Shunmagan (CRT) 2 (11)560 (224)>3,8 h 2012ASSERT 0,69 vs 1,69 (51) 2580 (261)6mn – 18h 2014 SOS AF project (TRENDS, PANORAMA, Clinicalservice) 0,32 vs 0,67 (95) (4306)1 h Few events≈ 40 %AF In PM and IAD

5min1h6h12h24h 6min53min3.6h 17.7h 0.32% 0.43%0.67%0.44% 0.69%1.23%1.18%0% 4.89% SOS AF Project (Trends, Panorama, clinical service), n= (95) ASSERT, n= 2580 (51) Healey, NEJM 2014 AF burden

Boriani, Eur Heart Journal 2014Botto, J Cardiovasc Electrophy AF burden

Risk of stroke according to the FA type Vanassche, Eur Heart Journal 2015 Paroxystic vs permanent CHADSVASC FA parox = 0.8% stroke/year

Boriani, Eur Heart Journal 2014Botto, J Cardiovasc Electrophy 2009 DONC: 1h si CHADSVASC >0 5minutes si CHADS2>1 Conclusion In silent AF and patients with pace maker of defibrillator CHADS2VAS2C 0 => no anticoagulants CHADS2VAS2C ≥ 2 => anticoagulant if AF > 5-6 minutes CHADS2VAS2C 1 => anticoagulant only if AF> 1h (18h), paroxystic ?

Can we stop the anticoagulation ? Is AF a cause of stroke, or an associated factor? 2) Temportal link between AF and TE

IMPACT study (n=2718) Endpoint: TE + bleeding Randomized: Intermittent AOC vs continuous AOC Population: Implantable defibrillators Martin, European Heart Journal 2015

6 month before TE

Atrial fibrillation may be a marker of more generalized « atriopathy » 1/3 1/3 1/3 prior >30 days prior <30 days after

Rôle of Atriopathy ? Akoum, J Cadiovascular Electrophysiol. 2013

Conclusion: How subcutaneus monitoring does change our daily practice 1. AF burden and silent AF with PM or IAD : early detection CHADS2VAS2C 0 => no d’anticoagulants CHADS2VAS2C ≥ 2 => anticoagulant if AF > 5-6 minutes CHADS2VAS2C 1 => anticoagulant only if AF > 1h, 18h, paroxystic ? 2. Few temporal link between AF and stroke

Expecting : REACT.COM study Randomized: Intermittent AOC vs continuous AOC Population: AF and CHADS 1/2 Randomized: Intermittent AOC vs continuous AOC ?

YearStudy: n TE (n in AFAF prior > 30 days AF prior < 30 days After only 2009TRENDS: 40 (26)9 (35%)11(42%)6 (23%) 2012ASSERT: 51 (26)18(69%)8 (31%) 1/3 1/3 1/3 prior >30 days prior <30 days after